- Home
- TTGT vs ESPR Comparison
TTGT vs ESPR Comparison
Compare TTGT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- ESPR
- Stock Information
- Founded
- TTGT 1999
- ESPR 2008
- Country
- TTGT United States
- ESPR United States
- Employees
- TTGT N/A
- ESPR N/A
- Industry
- TTGT Telecommunications Equipment
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- ESPR Health Care
- Exchange
- TTGT Nasdaq
- ESPR Nasdaq
- Market Cap
- TTGT 468.3M
- ESPR 534.3M
- IPO Year
- TTGT 2007
- ESPR 2013
- Fundamental
- Price
- TTGT $5.16
- ESPR $2.85
- Analyst Decision
- TTGT Strong Buy
- ESPR Buy
- Analyst Count
- TTGT 5
- ESPR 6
- Target Price
- TTGT $16.40
- ESPR $6.50
- AVG Volume (30 Days)
- TTGT 362.4K
- ESPR 6.7M
- Earning Date
- TTGT 11-10-2025
- ESPR 11-06-2025
- Dividend Yield
- TTGT N/A
- ESPR N/A
- EPS Growth
- TTGT N/A
- ESPR N/A
- EPS
- TTGT N/A
- ESPR N/A
- Revenue
- TTGT $387,100,000.00
- ESPR $268,125,000.00
- Revenue This Year
- TTGT $73.47
- ESPR $18.83
- Revenue Next Year
- TTGT $3.95
- ESPR N/A
- P/E Ratio
- TTGT N/A
- ESPR N/A
- Revenue Growth
- TTGT 50.73
- ESPR N/A
- 52 Week Low
- TTGT $5.15
- ESPR $0.69
- 52 Week High
- TTGT $33.08
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TTGT 37.39
- ESPR 54.35
- Support Level
- TTGT $5.42
- ESPR $2.80
- Resistance Level
- TTGT $6.12
- ESPR $3.01
- Average True Range (ATR)
- TTGT 0.29
- ESPR 0.16
- MACD
- TTGT -0.04
- ESPR -0.00
- Stochastic Oscillator
- TTGT 1.54
- ESPR 55.90
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.